HIMS news

Latest 11 stories · newest Oct 23, 2026

HIMS
10 Health Care Stocks Whale Activity In Today’s Session
HIMS
10 Health Care Stocks With Whale Alerts In Today’s Session
HIMS
8 Health Care Stocks Whale Activity In Today’s Session
HIMS
10 Health Care Stocks Whale Activity In Today’s Session
HIMS
FDA Says It Has Received 990 Adverse Event Reports Tied To Compounded Semaglutide And More Than 730 Tied To Compounded Tirzepatide; Establishes Import Alert For Compounded GLP-1 Active Pharmaceutical Ingredients
HIMS
Hims & Hers Q2 2026 results beat expectations with revenue up 38%

Hims & Hers Health reported $753.2M Q2 revenue, up 38% YoY, and raised 2026 full-year guidance to $3.1B-$3.3B. Subscribers reached 2.89M.

HIMS
Hims & Hers enters Master Receivables Purchase w/ JPMorgan

Subsidiaries XeCare and Apostrophe finalized a new credit facility with JPMorgan Chase. This financing deal aims to bolster cash flow and working capital.

HIMS
10 Health Care Stocks Whale Activity In Today's Session
HIMS
Hims & Hers amends revolving credit facility with lenders for third time since Feb 2025

Hims & Hers Health executed Amendment No. 3 to its revolving credit agreement dated May 29, 2026, with JPMorgan Chase as administrative agent. The multiple amendments within 16 months suggest the company is actively managing its credit facility terms.

HIMS
Hims & Hers issues $0.00% convertible senior notes due 2032

Hims & Hers Health entered into an indenture with U.S. Bank Trust Company for convertible senior notes dated May 21, 2026. The offering provides the company with debt financing and conversion equity options for investors.

HIMS
Hims & Hers announces $300M convertible notes offering due 2032

Hims & Hers plans to issue $300 million of convertible senior notes maturing in 2032, with a $45 million greenshoe option, to fund international expansion including the Eucalyptus acquisition and AI platform investments. The offering provides capital flexibility while the company pursues growth in t…

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same HIMS feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/HIMS/newsSTART FREE